About Javeri
Product & Services
Equity
Derivatives
Mutual Funds
IPO
Corporate Info
Research
Contact Us
Corporate Info
Smart Quotes
Company Background
Board of Directors
Balance Sheet
Profit & Loss
Peer Comparison
Cash Flow
Shareholdings Pattern
Quarterly Results
Share Price
Deliverable Volume
Historical Volume
MF Holdings
Financial Ratios
Directors Report
Price Charts
Notes Of Account
Management Discussion
Beta Analysis
Board Meetings
Corporate Announcements
Book Closure
Record Date
Bonus
Company News
Bulk Deals
Block Deals
Monthly High/low
Dividend Details
Bulk Deals
Insider Trading
Advanced Chart
HOME
>
CORPORATE INFO
>
BOARD MEETINGS
Board
Meetings
Ipca Laboratories Ltd.
From Date
:
To Date
:
Source Date
Board Meeting Date
Details
24-Oct-2024
14-Nov-2024
Quarterly Results & Interim Dividend
23-Sep-2024
30-Sep-2024
Inter alia, to consider and approve:- (1) Integration and consolidation of the generics formulations business in the US market of M/s. Bayshore Pharmaceuticals LLC (wholly owned step-down subsidiary) into Unichem Pharmaceuticals (USA) Inc. (wholly owned subsidiary of Company?s subsidiary)
24-Jul-2024
13-Aug-2024
Quarterly Results
07-May-2024
29-May-2024
Final Dividend & Audited Results
23-Jan-2024
14-Feb-2024
Quarterly Results
25-Oct-2023
10-Nov-2023
Quarterly Results & Interim Dividend
21-Jul-2023
10-Aug-2023
Quarterly Results
12-May-2023
29-May-2023
Audited Results
20-Jan-2023
14-Feb-2023
Quarterly Results
02-Nov-2022
11-Nov-2022
Quarterly Results & Interim Dividend
28-Jul-2022
10-Aug-2022
Quarterly Results
12-May-2022
24-May-2022
Audited Results & Amalgamation
31-Jan-2022
14-Feb-2022
Quarterly Results
20-Oct-2021
13-Nov-2021
Interim Dividend & Stock Split & Quarterly Results
22-Jul-2021
05-Aug-2021
Quarterly Results
17-May-2021
28-May-2021
Audited Results
19-Jan-2021
04-Feb-2021
Quarterly Results
27-Oct-2020
07-Nov-2020
Interim Dividend & Quarterly Results
26-Aug-2020
02-Sep-2020
IPCA LABORATORIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 02/09/2020 ,inter alia, to consider and approve allotment of 5,00,000 equity shares of Rs. 2/- each fully paid-up of the Company to the members of the Promoters / Promoter Group upon conversion of warrants issued to them at the meeting of the Board of Directors of the Company held on 7th November, 2019 and pursuant to a resolution passed by the shareholders of the Company at the Extra Ordinary General Meeting held on 24th October, 2019. & Preferential Issue of shares
29-Jul-2020
10-Aug-2020
Quarterly Results
Page
1
of
6
Prev
||
Next
Disclaimer
|
Privacy Policy
| Grievance |
FAQ
|
Sitemap |
Client Registration |
Useful Links
|
Anti Money Laundering
|
Inactive Client Policy
|
Scores
Vernacular Kyc
|
Advisory For Investors
|
Investor Adviser
|
Filing complaints on SCORES - Easy & quick
|
Policy on PMLA
Publishing of investor charter information
|
Annexure A – Investor charter of brokers
|
Annexure A – Investor charter of DP
|
Annexure B –Linked content for information to charter for DP
|
Annexure B & C (investor complaint data) broker & DP
Investor Charter & Complaints
|
Advisory-KYC Compliance
|
E-Voting NSE
|
E-Voting BSE
|
Details of Client Bank Accounts
|
Risk Disclosure
|
NSE FO Risk disclosure
SEBI Regn. No.: INB010997431 (BSE), INB230997430 (NSE)
Copyright 2008 Javeri Fiscal Services Ltd.
Designed , Developed & Content Powered by
Accord Fintech Pvt. Ltd.
CLOSE
X
RISK DISCLOSURES ON DERIVATIVES
9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
On an average, loss makers registered net trading loss close to ₹ 50,000.
Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.
Source:
Click Here.